Shilpa Medicare is currently trading at Rs. 382.00, up by 8.35 points or 2.23% from its previous closing of Rs. 373.65 on the BSE.
The scrip opened at Rs. 378.50 and has touched a high and low of Rs. 382.50 and Rs. 375.00 respectively. So far 177 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 546.95 on 14-Sep-2018 and a 52 week low of Rs. 328.05 on 02-Apr-2019.
Last one week high and low of the scrip stood at Rs. 387.45 and Rs. 360.30 respectively. The current market cap of the company is Rs. 3065.41 crore.
The promoters holding in the company stood at 53.80%, while Institutions and Non-Institutions held 26.57% and 19.63% respectively.
Shilpa Medicare has received US Food and Drug Administration’s (USFDA) final approval for its ANDA, Docetaxel Injection USP, 20 mg/mL, 80 mg/4 mL (20 mg/mL), and 160 mg/8 mL (20 mg/mL).
Docetaxel Injection USP, 20 mg/mL, 80 mg/4 mL and 160 mg/8 mL is a generic equivalent of reference listed drug (RLD) Taxotere used in the treatment of Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Gastric Adenocarcinoma, Head and Neck Cancer as recommended in the label approved by USFDA.
According to IQVIA MAT Q1 2019 data, the US market for Docetaxel Injection USP is approximately $32.13 million.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1529.55 |
Dr. Reddys Lab | 6315.00 |
Cipla | 1423.40 |
Zydus Lifesciences | 1021.00 |
Lupin | 1679.75 |
View more.. |